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Preferential Myosin Heavy Chain Isoform B Expression May
Contribute to the Faster Velocity of Contraction in Veins versus
Arteries
By Catherine M. Rondelli, Irna T. Szasz, Anas Kayal, Keshari Thakali, Ralph E. Watson,
Arthur S. Rovner, Thomas J. Eddinger, Gregory D. Fink, and Stephanie W. Watts
Smooth muscle myosin heavy chains occur in 2 isoforms, SMA (slow) and SMB (fast).
We hypothesized that the SMB isoform is predominant in the faster-contracting rat vena cava
compared to thoracic aorta. We compared the time to half maximal contraction in response to a
maximal concentration of endothelin-1 (ET-1; 100 nM), potassium chloride (KCl; 100 mM) and
norepinephrine (NE; 10 µM). The time to half maximal contraction was shorter in the vena cava
compared to aorta (aorta: ET-1 = 235.8 ± 13.8 s, KCl = 140.0 ± 33.3 s, NE = 19.8 ± 2.7 s; vena
cava: ET-1 = 121.8 ± 15.6 s, KCl = 49.5 ± 6.7 s, NE = 9.0 ± 3.3 s). Reverse-transcription
polymerase chain reaction supported the greater expression of SMB in the vena cava compared
to aorta. SMB was expressed to a greater extent than SMA in the vessel wall of the vena cava.
Western analysis determined that expression of SMB, relative to total smooth muscle myosin
heavy chains, was 12.5 ± 4.9-fold higher in the vena cava compared to aorta, while SMA was 4.9
± 1.2-fold higher in the aorta than vena cava. Thus, the SMB isoform is the predominant form
expressed in rat veins, providing one possible mechanism for the faster response of veins to
vasoconstrictors.

Introduction
The myosin proteins are a large superfamily of proteins that share a common motor
domain which, through interacting with actin and adenosine triphosphate (ATP) hydrolysis,
produces movement. There are at least 15 classes of myosin, of which smooth muscle myosin is
in class II [1] . Members of myosin class II are hexameric enzymes that are composed of 2 heavy
chains and 2 pairs of light chains. Myosin has 3 functional subdomains: (1) the motor domain
which interacts with actin and binds ATP, (2) the neck domain which binds light chains or
calmodulin and (3) the tail which anchors myosin to filaments in the muscle wall [1, 2].
Alternative splicing of the heavy chain of class II myosin (MHC) produces 4 MHC
isoforms (1A, 1B, 2A, 2B) [for head isoforms, see 3–5; for tail isoforms, see 6–8]. MHC 1 and
MHC 2 differ only at the carboxy terminus of the myosin tail, while SMA lacks a 7 amino acid
insert in the ATP binding pocket of the motor domain head which is present in SMB [2, 9]. SMB
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has higher ATPase activity, faster actin translocation velocity [10]

and faster unloaded

shortening velocity than SMA [11], allowing for faster stretch activation and tension unloading
(activity via electrical stimulation) [12].
Much of the work regarding tissue-specific myosin isoform expression relates to striated
tissue (skeletal and cardiac) or isolated cardiac and vascular smooth muscle cells. Little has
been reported about intact smooth muscle vascular tissue at the protein level, although mRNA
analysis has shown increased SMB expression in fetal tissue [13], isolated cardiac smooth
muscle cells [14], lymphatic tissue [15] and specific organs such as the stomach [11] and kidney
[16]. Meer and Eddinger [17], Eddinger et al. [18] and Eddinger and Meer [19] have shown that
while the head isoforms (SMA and SMB) correlate with unloaded shortening in single cells, this is
not the case for the tail isoforms (SM1 and SM2) for MLC17 (A and B). We and others have
shown that veins contract faster than arteries to agonists [20, 21] , despite proportionally fewer
smooth muscle cells present in veins compared to arteries. Therefore, we hypothesized that
increased SMB expression in veins compared to arteries allows veins to contract faster than
arteries.

Methods
Animals
Male Sprague-Dawley rats (0.225–0.250 kg; Charles River, Portage, Mich., USA) were
used. Experiments were approved by the Michigan State University Institutional Animal Use and
Care Committee.
Smooth Muscle Isometric Contractile Measurement
–1

Rats were deeply anesthetized with pentobarbital intraperitoneally (50 mg kg ) to the
point of a loss of corneal reflex and lack of withdrawal from painful stimuli. Thoracic aorta, vena
cava and tail artery were placed in physiologic salt solution consisting of (in mM): NaCl, 130; KCl,
4.7; KH2PO4, 1.18; MgSO4-7H2O, 1.17; CaCl2-2H2O, 1.6; NaHCO3, 14.9; dextrose, 5.5;
CaNa2EDTA, 0.03. Tissues were cleaned of fat and connective tissue, left with an intact
endothelium, mounted as rings (3–4 mm long) on stainless steel hooks and placed on stainless
steel holders in tissue baths (30 ml) for isometric tension recordings using Grass polygraphs and
transducers as previously described [22]. Functional integrity of the endothelial cells was
evaluated by testing relaxation caused by acetylcholine (1 µM) in tissues contracted with 10–100
nM α-adrenergic agonist norepinephrine (vein) or phenylephrine (artery). Individual tissues were
challenged with a maximal concentration of endothelin (ET-1; 100 nM), potassium chloride (KCl;
100 mM) and norepinephrine (NE; 10 µM), and the time to half maximal contraction was
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measured in seconds. Each tissue was exposed to 2 agonists. NE or KCl was added first, and
additions were randomized throughout the experiments. Tissues were then washed for 1 h, with
washes every 5 min. ET-1 was then added, as contraction stimulated by ET-1 is virtually
irreversible and difficult to wash out.
Reverse Transcription and Polymerase Chain Reaction
The MELT

TM

total RNA isolation system (Ambion, Austin, Tex., USA) was used according

to the manufacturer’s instructions. Briefly, 10-mg sections of rat tail artery, thoracic aorta and
vena cava were cleaned in cold nuclease-free water and enzymatically digested while being
vortexed. The homogenate was bound to magnetic beads for RNA purification, DNAse digestion
and washing. A magnetic stand adapted for 96-well plates was used to recapture the RNA
binding beads throughout the experiment. RNA was finally eluted from the magnetic beads in
10–20 fl elution solution. Total RNA was quantitated on a Nanodrop spectrophotometer. The
A260/280 and A260/230 ratios were considered acceptable if they were situated around 2
(80.15). The integrity of RNA was assessed by MOPS formaldehyde gel electrophoresis when
the RNA isolation method was initially established, however, vena cava RNA yield (usually
around 1 µg) did not allow for repeating this verification with each sample.
Primers for rat SMA/SMB were based on those reported by Shiraishi et al. [16]. SMB
mRNA contains a 21-nucleotide insert in the 5'-end coding region that is lacking in SMA mRNA.
The primers were 5'-TACAGAAGCATGCTACAAGATCGT-3' and
5'-GCGGGAGGAGTTGTCATTCTTGAC-3'. Primers for β2-microglobulin, as a housekeeping
gene, were purchased as a kit from Super Array (Frederick, Md. USA).
One microgram of total RNA, DNAse treated, was used as starting material for all
samples. First-strand cDNA synthesis was performed using oligo(dT)12–18, dNTP, 5x
first-strand buffer, 0.1 M DTT and the Superscript II reverse transcriptase (Invitrogen, Carlsbad,
Calif., USA) in a 1-hour incubation at 42°C, followe d by a 15-min 70°C incubation for reverse
transcriptase denaturation. Conventional polymerase chain reaction using the Platinum Taq High
Fidelity DNA polymerase (Invitrogen) was performed, and final products separated on a 3%
agarose gel in Tris-acetate-EDTA buffer using DNA ladders separated by 100 bp (Invitrogen).
Immunohistochemistry
Sections of formalin-fixed, paraffin-embedded thoracic aorta and vena cava (8 fm) were
cut, air dried overnight, deparaffinized, and taken through standard protocol using a Vector kit.
Slides for smooth muscle α-actin were unmasked through the Vector Laboratory Antigen
Unmasking protocol, modified to use a microwave instead of a pressure cooker. After blocking
with 1.5% serum in phosphate-buffered saline (PBS), sections incubated overnight at 4°C with
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an antibody for total (SMA + SMB) MHC [1 µg/ml, mouse antibody from Santa Cruz
Technologies (Santa Cruz, Calif., USA), with 1.5% blocking serum in PBS], SMB antibody (1:20,
with 1.5% blocking serum in PBS), SMA antibody (1:100, with 1.5% blocking serum in PBS),
smooth muscle α-actin (0.5 fg/ml, mouse antibody from Calbiochem, with 1.5% blocking serum in
PBS) or no antibody (1.5% blocking serum in PBS). SMB antibody was generated in the
laboratory against the short peptide sequence QGPSFAYGELEC in rabbit [23]. SMA antibody
was generated in the laboratory against the short peptide sequence KKDTSITGELEC in rabbit
[11]. Sections were washed thrice with PBS, incubated for 30 min with the appropriate secondary
antibody, washed again and incubated for 30 min with Vector ABC Elite reagent. Antibody
binding was detected by incubating sections for 1 min with a DAB developing solution (Vector
Laboratories, Burlingame, Calif., USA). Primary antibody binding was observed by a dark
brown/black precipitate. Sections were photographed using an inverted Nikon T2000 microscope
connected to a SPOT Insight color camera using MetaMorph® software. Images were processed
using Adobe® Photoshop. Masson’s trichrome staining was performed by the Investigative
Histopathology Laboratory at Michigan State University
Western Analysis
Tissues were isolated directly from the animal, cleaned and snap-frozen in liquid nitrogen.
Tissue lysates were prepared as previously described [24]. Fifty micrograms of total protein was
boiled for 5 min with standard 4:1 sample buffer. Proteins were separated on 1-mm-thick, 7%
polyacrylamide SDS gels using a Mini Bio-Rad III apparatus with a positive control for SMB of rat
tail artery homogenate [25], and transferred to Immobilon PVDF membranes. Membranes were
blocked overnight in 5% milk (4°C, PBS + 0.025% NaN 3) and blots were incubated with primary
antibodies [1:500 total smooth muscle MHC (SM-MHC), 1: 1,000 SMB, 1:1,000 SMA] for 24 h at
4°C. Blots were then rinsed thrice in Tris-buffered saline + Tween (0.1%) with a final rinse in
Tris-buffered saline and incubated with a horseradish peroxidase-linked antirabbit secondary
antibody (1:2,000; Cell Signaling Technology, Beverly, Mass., USA) for 1 h at 4°C (rocking).
ECL®

reagents (Amersham Life Sciences, Arlington Heights, Ill., USA) were used to visualize

bands. Gels were stained with Gel Code Blue® (Pierce, Rockford, Ill., USA) to verify protein
loading and blots were reprobed with smooth muscle α-actin primary antibody (1:1,000;
Oncogene Research Products, Boston, Mass., USA).
Data Analysis
Data are presented as means ± SEM for the number of animals in parentheses. Time to
half maximal contraction is reported as seconds. Band density was quantified using the public
domain program NIH Image (version 1.62). When comparing 2 groups, the appropriate Student t
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test was used. ANOVA followed by the Student Newman Keuls post hoc test was performed
when comparing 3 or more groups. In all cases, p ≤ 0.05 was considered statistically significant.

Results
Vena Cava Contract Faster than Aorta to Exogenous ET-1, KCl and NE
Rat aorta and vena cava from the same animal were stimulated with a maximal
concentration of ET-1 (100 nM), KCl (100 mM) and NE (10 fM). In separate experiments, the
speed of response of the tail artery to these same agonists was investigated.

Figure 1a depicts

a raw tracing of the tail artery, aorta and vena cava response to a maximal concentration of ET-1
(100 nM). In general, vena cava generated significantly less tension than aorta due to the lower
muscle mass present per milligram of tissue. In the contractile experiments, tissues responded to
the 3 agonists in the following manner: aorta NE: 3,325 ± 480 mg, vena cava NE: 96 ± 16 mg;
aorta KCl: 2,470 ± 344 mg, vena cava KCl: 222 ± 31 mg; aorta ET-1: 1,855 ± 242 mg, vena cava
ET-1: 553 ± 57 mg. The time to half maximal contraction was significantly shorter in veins
compared to arteries, regardless of agonist. Time to half maximal contraction ranged from 1.94to 2.83-fold lower in the vein compared to the artery (aorta ET-1: 236 8 14 s, vena cava ET-1:
122 ± 16 s; aorta KCl: 140 ± 33 s, vena cava KCl: 50 ± 7 s; aorta NE: 20 ± 3 s, vena cava NE: 9 ±
3 s; fig. 1b). By comparison, the tail artery – a thermoregulatory artery – was used as a control for
an SMB-positive tissue and contracted with significant speed to these 3 agonists (ET-1 = 29.3 ±
2.0 s, KCl = 6.1 ± 0.5 s, NE = 3.2 ± 0.2 s).
SMB mRNA Is Observed at a Higher Magnitude in Vena Cava Compared to Aorta
Primers designed to detect the mRNA variants for SMA and SMB were used in equivalent
amounts of cDNA generated from tail artery, aorta and vena cava. As expected, 2 products were
observed at 261 bp (SMB) and 240 bp (SMA) (fig. 2). While aorta weakly expressed SMB, all
vena cava examined expressed a significantly higher amount of SMB message as densitometry
revealed an increase of over 200% of that observed in the aorta. By comparison, the tail artery
provided a robust signal for SMB and a weaker signal for SMA. Thus, these data validate our use
of the tail artery as a positive control for SMB and demonstrate the potential for preferential
expression of SMB protein in the vena cava compared to the aorta.
Stronger Immunohistochemical Staining for SMB Is Observed in Vena Cava Compared to
Aorta
Paraffin-embedded sections from normal rats were used in the immunohistochemical
analysis of SM-MHC isoforms. Masson’s trichrome staining of the aorta (fig. 3a) and vena cava
(fig. 4a) demonstrates significantly different structures of arteries and veins. The aorta has
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several distinct and regular layers of smooth muscle cells that run parallel to the intimal
endothelium, as confirmed by α-actin staining. The arterial adventitia was primarily a collagenous
layer surrounding the highly organized muscle. In contrast, trichrome staining of the vena cava
revealed a collagenous and relatively disorganized tissue with a thin layer of smooth muscle
underneath the endothelial layer, as confirmed by α-actin staining (fig. 4a). Total SM-MHC and
SMB expressions were spread relatively uniformly throughout the arterial wall from the
endothelium to the adventitia with similar patterns weakly seen with SMA (fig. 3b). Total
SM-MHC expression in the vena cava appears to be limited to the endothelial/ subendothelial
cell layer while SMB and to a significantly lesser extent SMA expression was observed
throughout the collagenous vein wall (fig. 4b).
Western Analysis Demonstrates Higher SMB Expression in Vena Cava than Aorta
Figure 5a shows Western blots of total SM-MHC, SMB and SMA expression in aorta and
vena cava. Rat tail artery was used as a positive control for SMB [16]. Densitometry of total
SM-MHC, SMB and SMA expression was normalized to the expression of smooth muscle α-actin
present in a given sample (fig. 5b). There was notably less α-actin present per microgram of
tissue in the vein compared to the artery (fig. 5 c). While total SMMHC and SMA expression was
significantly less in vena cava compared to aorta, SMB isoform expression tended to be higher in
the vena cava than aorta (fig. 5b). The relative expression of SMA to the total SM-MHC
expression was significantly greater (4.9 ± 1.2-fold) in the aorta compared to vena cava. The
relative expression of SMB to the total MHC expression was significantly greater (12.5 ± 4.9-fold)
in the vena cava compared to aorta.

Discussion
The ability of vasculature to respond to contractile stimuli from neuronal innervation and
blood is crucial for stable maintenance of blood pressure. The measurably different speed of
contraction between arteries and veins suggests an important role of venous contractility in the
moment-to-moment control of blood pressure, allowing for a quick response to natural stimuli.
For example, blood must quickly be redirected from the lower body towards the head upon
movement from a reclining to a vertical position to avoid loss of consciousness. The present
work begins to define one possible mechanism by which the fast response of veins to stimuli is
facilitated.
Time to Half Maximal Contraction Is Less in Veins versus Arteries
Interestingly, each of the vasoconstrictor stimuli tested demonstrated a significant
difference in response time between tissues, and vena cava consistently contracted faster than
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aorta. The tail artery, which possesses predominantly SMB protein, had the fastest time to half
maximal contraction for all agonists examined. The agonists used elicit contraction via different
mechanisms. ET-1 binding to ETA and ETB receptors activates phospholipase C-β to increase
2+

2+

intracellular Ca [26]. KCl causes membrane depolarization and extracellular Ca influx through
2+

L-type calcium channels [27] while Ca intercellular release minimally contributes to contraction
[28]. NE binds α-adrenergic receptors which leads to G protein-coupled increase in intracellular
2+

Ca [29, 30]. Though membrane depolarization is a common factor between each of the
agonists tested [2, 24, 25, 31], the mechanisms by which these agonists cause contraction are
varied enough to consider the difference in relative speed of contraction in artery and vein to be
an inherent property of these tissues. We proposed that differences in SM-MHC isoform
expression in arteries and veins may account for differences in speed of contraction.
Structural Characteristics of Arteries and Veins
The architecture of the aorta and vena cava were strikingly different. The qualitative
difference between the smooth muscle tissue of aorta and the predominantly more structural
collagen fibers of vena cava can be seen in figures 3 and 4. We have assumed that vascular
smooth muscle cells are wholly responsible for contraction of aorta and vena cava. The question
has been raised as to whether this is a fair assumption given the relative paucity of smooth
muscle in veins. The pronounced SMB staining in figure 4 compared to total MHC staining is
likely due to the sensitivity of the respective antibodies in this particular protocol, as is the
comparably lighter SMA staining in all tissues. It is possible that the relative penetrance of
antibodies in arterial versus venous tissues is different, thereby explaining why there is less
staining for total MHC than for SMB.
One potential concern is that the basic passive elements of the blood vessels contribute
to the speed of contraction. This is possible, but it is not an avenue we have yet explored. Veins
and arteries possess different complements of framework proteins. Arteries are more highly
elastic than veins, while veins are compliant vessels that can allow for the pooling of blood. One
potential way to determine the contribution of the passive framework to contraction would be to
investigate the kinetics of contraction in the freshly dissociated, isolated vascular smooth muscle
cell from the vein and the artery. This will be an interesting question to examine.
Role of SMB in Contraction
A recent provocative study performed in renal blood vessels was the stimulus for
investigating the expression of faster SMB in arteries and veins. Shiraishi et al. [16] performed
immunohistochemical and Western analysis of MHC in renal afferent and efferent arterioles. The
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connection between similar kinetic features and physiological roles led us to quantitate SMB,
which has been suggested by others to be an important intrinsic difference in these tissues [16,
23]. Shiraishi et al. [16] noted that there was little to none of the fast isoform (SMB) in the
slower-contracting efferent arterioles, although total SMMHC measurements did show the
presence of some form of SM-MHC. In contrast, faster-contracting afferent arterioles expressed
significantly more SMB. Afferent arterioles were comparable to veins in their ability to rapidly
contract to chemical depolarization of the membrane. Efferent arterioles were similar to arteries
in depolarization response, which is significantly slower than in afferent arterioles. With Western
analysis, we observed a similar difference in the relative expression of SMB to total SMMHC
protein. The vena cava has a significantly greater expression of SMB than the aorta, though total
SM-MHC content is less. As expected, the reverse was true for SMA, as relative expression of
SMA to total SM-MHC was higher in the aorta than the vena cava. We used a colorimetric
detection system for our immunohistochemistry instead of the fluorescence system used in the
paper by Shiraishi et al. [16] due to the intense amount of autofluorescence observed in the
whole tissue.
The tail artery was used throughout this study as a positive control for SMB expression;
this was originally reported by Shiraishi et al. [16]. We were able to validate the preferential
expression of SMB mRNA and protein in the tail artery. The tail artery does express some SMA
mRNA and protein (fig. 2, 5). Moreover, it is an artery, and we are here trying to argue that the
general mechanics of contraction, as based on SM-MHC function, are different between veins
and arteries. However, the rat tail artery is a unique artery in its dedication to thermal regulation
of the rat. It is the vasodilation of this artery that enables a rat to shed heat, and it is thus
governed by stimuli that are significantly different from those which would govern a systemic
artery. Thus, while there are limitations to using the tail artery, it provides one of the best controls
available when examining SMB expression and in connecting our work to that of others.
Limitations and Questions
There are no specific pharmacologic inhibitors of SMA or SMB to further examine our
hypothesis. An ideal experiment would be to knock down native SMB to compare the speed of
vessel contraction in the presence and absence of SMB. Periasamy’s group has generated an
SMB knockout mouse and other laboratories have used this model with conflicting results [32,
33]. While Karagiannis and Brozovich [32] demonstrated differences in shortening velocities of
bladder smooth muscle tissue between normal and the slower knockout mice, no direct
visualization methods were used to confirm the total loss of SMB in the target tissue. However,
Patzak et al. [33] did not observe differences in constriction velocity between efferent and
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afferent arterioles of normal and SMB knockout mice. While the loss of SMB was confirmed
through immunohistochemistry, the possibility of compensatory mechanisms masking changes
in physiology could not be ruled out. We have also not addressed the potential differences
between arteries and veins in the SM1 and SM2 class of MHC proteins, and thus, we cannot
comment upon how these particular proteins may contribute to the kinetics of agonist-induced
contraction.
One potential concern is the finding that while the vein possessed a greater amount of
protein and mRNA for SMB as opposed to SMA, the relative amount of mRNA did not
correspond exactly with the protein expressed. This is somewhat different than what was found
by Shiraishi et al. [16] in the afferent/efferent arterioles. We did confirm the nearly pure
expression of the SMB isoform in the tail artery and thus have faith in the primer sets used. One
speculation for the discrepancy in these findings is that the SMB mRNA may be more efficiently
translated than the SMA mRNA, clearly the dominant mRNA form in the vena cava but not the
dominant protein.
Finally, other factors which influence arterial versus venous contraction may exist in
smaller arteries and veins that we do not see in the large vessels. What are the differences in the
rates of signal transduction pathways for each agonist in each tissue? Are there cellular
composition differences not detected in the trichrome staining that may contribute to a contractile
response, such as the presence of myofibroblasts? These remain unanswered questions.

Conclusion
In conclusion, we have quantitatively demonstrated that the proportion of SMB
expression is greater in veins compared to SMA. The vena cava had little to no measurable SMA
expression. The possibility that SMB plays a significant role in the kinetic contractile response
indicates the need for further experimentation, such as additional kinetic studies in the presence
of an SMB-specific inhibitor or SMB knockout. Nonetheless, the faster phenotype of veins versus
arteries is one argument for the important role played by veins in moment-to-moment control of
blood pressure.

Acknowledgment
This work was made possible by NIH grant PO1HL70687.

References
1. Sellers JR: Myosins: a diverse superfamily. Biochim Biophys Acta 2000;
Rondelli et al., 9

1496:3–22.
2. Ogut O, Brozovich FV: Regulation of force in vascular smooth muscle. J Molec
Cell Cardiol 2003; 35:347–355.
3. Hamada Y, Yanagisawa M, Katsuragawa Y, et al: Distinct vascular and intestinal
smooth muscle myosin heavy chain mRNAs are encoded by a single-copy gene in the
chicken. Biochem Biophys Res Commun 1990; 170: 53–58.
4. Kelly C, Takahashi M, Yu J, Adelstein R: An insert of seven amino acids confers
functional differences between smooth muscle myosins from the intestines and vasculature.
J Biol Chem 1993; 268:12848–12854.
5. White S, Martin A, Periasamy M: Identification of a novel smooth muscle myosin
heavy chain cDNA: isolation diversity in the S1 head region. Am J Physiol Cell Physiol 1992;
264:C1252–C1258.
6. Babij P, Periasamy M: Myosin heavy chain isoform diversity in smooth muscle is
produced by differential RNA processing. J Mol Biol 1989; 210:673–679.
7. Nagai R, Larson D, Periasamy M: Characterization of a mammalian smooth
muscle myosin heavy chain cDNA clone and its expression in various smooth muscle types.
Proc Natl Acad USA 1998; 85:1047–1051.
8. Nagai R, Kuro-o M, Babij P, Periasamy M: Identification of two types of smooth
muscle myosin heavy chain isoforms by cDNA cloning and immunoblot analysis. J Biol Chem
1989; 264:9734–9737.
9. Arner A, Lofgren M, Morano I: Smooth, slow and smart muscle motors. J Muscle
Res Cell Motil 2003; 24:165–173.
10. Rovner AS, Freyzon Y, Trybus KM: An insert in the motor domain determines the
functional properties of expressed smooth muscle myosin isoforms. J Muscle Res Cell Motil
1997; 18:103–110.
11. Eddinger T, Meer D: Single rabbit stomach smooth muscle cell myosin heavy
chain SMB expression and shortening velocity. Am J Physiol 2001; 280:C309–C316.
12. Pette D, Staron RS: Myosin isoforms, muscle fiber types, and transitions. Microsc
Res Tech 2000; 50:500–509.
13. White S, Zhou M, Low R, Periasamy M: Myosin heavy chain isoform expression in
rat smooth muscle development. Am J Physiol 1998; 275:C581–C589.
14. Sherwood J, Eddinger T: Shortening velocity and myosin heavy- and light-chain
isoform mRNA in rabbit arterial smooth muscle cells. Am J Physiol Cell Physiol 2002; 282:
C1092–C1102.
Rondelli et al., 10

15. Mutuchamy M, Gashev A, et al: Molecular and functional analysis of the
contractile apparatus in lymphatic muscle. FASEB J 2003; 17:920–922.
16. Shiraishi M, Wang X, Walsh M, et al: Myosin heavy chain expression in renal
afferent and efferent arterioles: relationship to contractile kinetics and function. FASEB J
2003; 17: 2284–2286.
17. Meer D, Eddinger T: Expression of smooth muscle myosin heavy chains and
unloaded shortening in single smooth muscle cells. Am J Physiol 1997; 273:C1259–C1266.
18. Eddinger T, Korwek A, Meer D, Sherwood J: Expression of smooth muscle
myosin light chain 17 isoforms and unloaded shortening in single smooth muscle cells. Am J
Physiol Cell Physiol 2000; 278:C1133–C1142.
19. Eddinger T, Meer D: Single rabbit stomach smooth muscle cell myosin heavy
chain SMB expression and shortening velocity. Am J Physiol Cell Physiol 2001;
280:C309–C316.
20. Hottenstien OD, Kreulen DL: Comparison of frequency dependence of venous
and arterial responses to sympathetic nerve stimulation in guinea-pigs. J Physiol 1987;
384:153–167.
21. Kreulen DL: Activation of mesenteric arteries and veins by preganglionic and
postganglionic nerves. Am J Physiol 1986; 251: H1267–H1275.
22. Thakali K, Fink G, Watts S: Arteries and veins desensitize differently to endothelin.
J Cardiovasc Pharmacol 2004; 43:387–393.
23. Low R, Mitchell J, Woodcock-Mitchell J, Rovner A, White S: Smooth-muscle
myosin heavy-chain SM-B isoform expression in developing and adult rat lung. Am J Respir
Cell Mol Biol 1999; 20:651–657.
24. Northcott C, Hayflick J, Watts S: Upregulated function of
phosphatidylinositol-3-kinase in genetically hypertensive rats: a moderator of arterial
hypercontractility. Clin Exp Pharmacol Physiol 2005; 32:851–858.
25. DiSanto ME, Cox RH, Wang Z, Chacko S: NH2-terminal-inserted myosin II heavy
chain is expressed in smooth muscle of small muscular arteries. Am J Physiol 1997; 272:
C1532–C1542.
2+

26. Zhang W, Kin M, Sham J: Endothelin-1 and IP3 induced Ca sparks in pulmonary
arterial smooth muscle cells. J Cardiovasc Pharmacol 2004; 44:S121–S124.
27. Heaps C, Parker J, Sturek M, Bowles D: Altered calcium sensitivity contributes to
enhanced contractility of collateral-dependent coronary arteries. J Appl Physiol 2004; 97:
310–316.
Rondelli et al., 11

28. Florian J, Watts S: Integration of mitogenactivated protein kinase kinase
activation in vascular 5-hydroxytryptamine2A receptor signal transduction. J Pharmacol Exp
Ther 1998; 284:346–355.
29. Zhong H, Minneman KP: a1-adrenoceptor subtypes. Eur J Pharmacol 1999;
375:261–276.
30. Varma DR, Deng XF: Cardiovascular a1-adrenocepter subtypes: functions and
signaling.

Can J Physiol Pharmacol 2000; 78:267–292.

31. Tanaka Y, Ishiro H, Nakazawa, T, Saito M, Ishii K, Nakayama K: Potentiation by
2+

2+

endothelin-1 of Ca sensitivity of contractile elements depends on Ca influx through L-type
2+

Ca channels in the canine cerebral artery. Gen Pharmac 1995; 26:855–864.
32. Karagiannis P, Brozovich F: Myosin heavy chain isoform expression regulates
shortening velocity in smooth muscle: studies using an SMB KO mouse line. J Muscle Res
Cell Motil 2004; 25:149–159.
33. Patzak A, Petzhold D, Wornski T, Martinka P, Babu G, Periasamy M, Haase H,
Morano I: Constriction velocities of renal afferent and efferent arterioles of mice are not
related to SMB expression. Kidney Int 2005; 68:2726– 2734.

Rondelli et al., 12

Appendix
Figure 1

a Tracing of the contraction to a maximal concentration of ET-1 in the rat tail artery, aorta and vena cava. The arrows on the tracings
indicate the time to half maximal contraction.
b Time to half maximal isometric contraction of rat aorta and vena cava in the presence of ET-1 (100 nM ), KCl (100 mM ) and NE (10
µM ). Bars represent means 8 SEM. * p ^ 0.05 vs. rat aorta; † p ^ 0.05 vs. vena cava.
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Figure 2

Polymerase chain reaction products for SMA (240 bp)/SMB (261 bp) and β2- microglobulin amplification of cDNA from rat tail artery,
rat aorta and rat vena cava. DNA ladders were run on both the left and right side of the gel. RTA = Rat tail artery; NTC = no template
control.
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Figure 3
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Figure 4
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Figure 5

a Western blot of total SM-MHC, SMB and SMA. The upper bands are SM-MHC, while the lower bands are the respective smooth
muscle α-actins. Each lane contains 50 µg total protein.
b Densitometry analysis of total SM-MHC, SMB and SMA expression. Each value was normalized to the relative density of α-actin.
c Relative difference in α-actin in aorta and vena cava per microgram protein. RA = Rat aorta; RVC = rat vena cava; RTA = rat tail
artery. * p ^ 0.05.
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